BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 11036292)

  • 21. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma.
    Kollmannsberger C; Oechsle K; Dohmen BM; Pfannenberg A; Bares R; Claussen CD; Kanz L; Bokemeyer C
    Cancer; 2002 May; 94(9):2353-62. PubMed ID: 12015760
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The possible role of F-18 FDG positron emission tomography in the differential diagnosis of focal pancreatic lesions.
    Papós M; Takács T; Trón L; Farkas G; Ambrus E; Szakáll S; Lonovics J; Csernay L; Pávics L
    Clin Nucl Med; 2002 Mar; 27(3):197-201. PubMed ID: 11852308
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is positron emission tomography using 18F-fluorodeoxyglucose and 11C-acetate valuable in diagnosing indeterminate pancreatic masses?
    Rasmussen I; Sörensen J; Långström B; Haglund U
    Scand J Surg; 2004; 93(3):191-7. PubMed ID: 15544073
    [TBL] [Abstract][Full Text] [Related]  

  • 24. F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer.
    Bares R; Klever P; Hauptmann S; Hellwig D; Fass J; Cremerius U; Schumpelick V; Mittermayer C; Büll U
    Radiology; 1994 Jul; 192(1):79-86. PubMed ID: 8208970
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: comparison with CT and US.
    Inokuma T; Tamaki N; Torizuka T; Magata Y; Fujii M; Yonekura Y; Kajiyama T; Ohshio G; Imamura M; Konishi J
    Radiology; 1995 May; 195(2):345-52. PubMed ID: 7724751
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Value of contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography in detection and presurgical assessment of pancreatic cancer: a prospective study.
    Buchs NC; Bühler L; Bucher P; Willi JP; Frossard JL; Roth AD; Addeo P; Rosset A; Terraz S; Becker CD; Ratib O; Morel P
    J Gastroenterol Hepatol; 2011 Apr; 26(4):657-62. PubMed ID: 21155879
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FDG-PET evaluation of indeterminate pancreatic masses.
    Ho CL; Dehdashti F; Griffeth LK; Buse PE; Balfe DM; Siegel BA
    J Comput Assist Tomogr; 1996; 20(3):363-9. PubMed ID: 8626891
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Retrospective digital image fusion of multidetector CT and 18F-FDG PET: clinical value in pancreatic lesions--a prospective study with 104 patients.
    Lemke AJ; Niehues SM; Hosten N; Amthauer H; Boehmig M; Stroszczynski C; Rohlfing T; Rosewicz S; Felix R
    J Nucl Med; 2004 Aug; 45(8):1279-86. PubMed ID: 15299049
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Utility of (18) F-FDG PET/CT and CECT in conjunction with serum CA 19-9 for detecting recurrent pancreatic adenocarcinoma.
    Rayamajhi S; Balachandran A; Katz M; Reddy A; Rohren E; Bhosale P
    Abdom Radiol (NY); 2018 Feb; 43(2):505-513. PubMed ID: 28900703
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-invasive differentiation of pancreatic lesions: is analysis of FDG kinetics superior to semiquantitative uptake value analysis?
    Nitzsche EU; Hoegerle S; Mix M; Brink I; Otte A; Moser E; Imdahl A
    Eur J Nucl Med Mol Imaging; 2002 Feb; 29(2):237-42. PubMed ID: 11926386
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases.
    Zimny M; Bares R; Fass J; Adam G; Cremerius U; Dohmen B; Klever P; Sabri O; Schumpelick V; Buell U
    Eur J Nucl Med; 1997 Jun; 24(6):678-82. PubMed ID: 9169578
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnosis of pancreatic carcinoma: role of FDG PET.
    Keogan MT; Tyler D; Clark L; Branch MS; McDermott VG; DeLong DM; Coleman RE
    AJR Am J Roentgenol; 1998 Dec; 171(6):1565-70. PubMed ID: 9843289
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Accuracy of 18F-FDG PET/CT, Multidetector CT, and MR Imaging in the Diagnosis of Pancreatic Cysts: A Prospective Single-Center Study.
    Kauhanen S; Rinta-Kiikka I; Kemppainen J; Grönroos J; Kajander S; Seppänen M; Alanen K; Gullichsen R; Nuutila P; Ovaska J
    J Nucl Med; 2015 Aug; 56(8):1163-8. PubMed ID: 26045314
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preoperative evaluation of pelvic masses with combined 18F-fluorodeoxyglucose positron emission tomography and computed tomography.
    Yamamoto Y; Oguri H; Yamada R; Maeda N; Kohsaki S; Fukaya T
    Int J Gynaecol Obstet; 2008 Aug; 102(2):124-7. PubMed ID: 18423470
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hyperaccumulation of (18)F-FDG in order to differentiate solid pseudopapillary tumors from adenocarcinomas and from neuroendocrine pancreatic tumors and review of the literature.
    Guan ZW; Xu BX; Wang RM; Sun L; Tian JH
    Hell J Nucl Med; 2013; 16(2):97-102. PubMed ID: 23687644
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ki-67 immunostaining in pancreatic cancer and chronic active pancreatitis: does in vivo FDG uptake correlate with proliferative activity?
    Buck AC; Schirrmeister HH; Guhlmann CA; Diederichs CG; Shen C; Buchmann I; Kotzerke J; Birk D; Mattfeldt T; Reske SN
    J Nucl Med; 2001 May; 42(5):721-5. PubMed ID: 11337566
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal masses.
    Ozülker T; Ozülker F; Ozbek E; Ozpaçaci T
    Nucl Med Commun; 2011 Apr; 32(4):265-72. PubMed ID: 21301376
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [18F] 3-deoxy-3'-fluorothymidine positron emission tomography: alternative or diagnostic adjunct to 2-[18f]-fluoro-2-deoxy-D-glucose positron emission tomography in the workup of suspicious central focal lesions?
    Halter G; Buck AK; Schirrmeister H; Wurziger I; Liewald F; Glatting G; Neumaier B; Sunder-Plassmann L; Reske SN; Hetzel M
    J Thorac Cardiovasc Surg; 2004 Apr; 127(4):1093-9. PubMed ID: 15052207
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Utility of 18 fludeoxyglucose in preoperative positon-emission tomography-computed tomography (PET-CT) in the early diagnosis of exocrine pancreatic cancer: A study of 139 resected cases.
    Sánchez-Bueno F; García-Pérez R; Claver Valderas MA; de la Peña Moral J; Frutos Esteban L; Ortiz Ruiz E; Fuster Quiñonero M; Parrilla Paricio P
    Cir Esp; 2016 Nov; 94(9):511-517. PubMed ID: 27712835
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [18 F-fluorodeoxyglucose positron emission tomography for characterization and initial staging of pancreatic tumors].
    Valinas R; Barrier A; Montravers F; Houry S; Talbot JN; Huguier M
    Gastroenterol Clin Biol; 2002 Oct; 26(10):888-92. PubMed ID: 12434099
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.